Glaxo, Merck Mull Cross-Licensing Patents For Cervical Cancer Vaccines

Law360, New York (December 8, 2004, 12:00 AM EST) -- U.K. drug maker GlaxoSmithKline PLC and German rival Merck & Co. Inc are in talks over a cross-licensing deal to share patents for cervical cancer vaccines at the center of a lawsuit filed by Indiana University.

“It's likely Merck and ourselves will reach an agreement on their intellectual property,” Duncan Learmouth, head of investor relations at Glaxo, told investors at an ING healthcare conference, according to Reuters.

The vaccines against the human papilloma virus, which causes most cases of the cervical cancer, could each become $2...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.